QSAM Biosciences Appoints Adriann Sax to Board of Directors
January 25, 2022 08:30 ET
|
QSAM Biosciences Inc.
Austin, TX, Jan. 25, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
QSAM Biosciences Receives Notice of Allowance for European Patent and Expands Licensed IP Portfolio
December 10, 2020 09:00 ET
|
QSAM Biosciences Inc.
Palm Beach, FL, Dec. 10, 2020 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Cyclosam® Samarium-153-DOTMP, for the...
QSAM Biosciences Advances Plan of Separation from Legacy Business
November 10, 2020 09:00 ET
|
QSAM Biosciences Inc.
Pharmaceutical Industry Experts Assume Leadership Roles at QSAM;Over $4M in Debt Eliminated from Balance Sheet Palm Beach, FL, Nov. 10, 2020 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM)...
QSAM Biosciences Starts Trading under New Symbol: QSAM
October 09, 2020 09:00 ET
|
QSAM Biosciences Inc.
Palm Beach, FL, Oct. 09, 2020 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM) announced today that it has commenced trading on The OTC Markets under the new stock symbol QSAM. The company’s...